On the stock market since 2010, it operates in the world of health and science. It has 143 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 11% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 73% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 8% a year on average.
Sales run at $49.7M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 17 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $14.6M against $49.7M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, RXMD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RXMD is a high-risk stock — not yet profitable, and its future rides on its product catching on.